cloprostenol and ceftiofur

The objectives of this study were to evaluate the efficacy of (1) administering ceftiofur hydrochloride in dairy cows with calving-related disorders to prevent metritis and (2) a combination of GnRH and PGF2α for the treatment of clinical endometritis, under Argentinean dairy farming conditions. Cows at high risk (HRC) for metritis (dystocia, RFM >12 h postpartum, hypocalcaemia, twins, or stillbirth) were randomly assigned to receive either 1.1 mg/Kg of ceftiofur hydrochloride on three consecutive days (HRC treated group HRCT, n = 110) or remained untreated (HRC control group HRCC, n = 126). Cows with low risk (LRC, no calving-related disorders, n = 868) did not receive any treatment (LRC group, n = 868). All cows were examined for metritis between days 4 and 10 and for clinical endometritis between 24 and 30 days postpartum. The body condition score (BCS) was recorded at both examinations. Cows with endometritis at days 24 to 30 postpartum received either 1.5 mg of D-cloprostenol (PGF; n = 129) or 100 μg of GnRH followed by D-cloprostenol after 7 days (GnRH+PGF, n = 119). There was no overall effect of treatment on the incidence of metritis or on time to pregnancy. Treatment, however, reduced the incidence of metritis in cows with high BCS (HRCT = 24.0 %, HRCC = 38.5 %) but had no effect in cows with low BCS (HRCT = 38.7 %, HRCC = 37.5 %). The proportion of pregnant cows by days in milk was greater (P < 0.01) in LRC group compared with that of the HRCT and HRCC groups. No significant differences were found between groups PG and PG+GNRH. GnRH+PGF treatment, however, tended (P = 0.06) to increase pregnancy rate in cows with a moderate loss of BCS (76.5 vs 65.2 %) but tended to reduce pregnancy rate (54.5 vs 76.0 %) in cows with a more pronounced loss in BCS (>0.75 points).

Topics: Animals; Anti-Bacterial Agents; Argentina; Cattle; Cattle Diseases; Cephalosporins; Cloprostenol; Endometritis; Female; Gonadotropin-Releasing Hormone; Oxytocics; Pregnancy; Reproduction; Risk Factors

The objective of the study was to compare the systemic antibiotic treatment of clinical endometritis in dairy cows with ceftiofur with a treatment protocol consisting of two doses of prostaglandin F(2alpha) analogue cloprostenol in a 14-d interval. On 2 commercial dairy farms, housing a total of 1900 Holstein cows, all cows that calved between June 2008 and January 2009 were examined 21-27d in milk (DIM) by vaginoscopy. Cows with clinical signs of endometritis, i.e. vaginal discharge containing flecks of pus, mucopurulent material or purulent mucus, were randomly allocated to one of two treatment groups. Cows in group CEF (n=141) received 1 mg/kg BW of ceftiofur (i.m.) on 3 consecutive days. Cows in group CLP (n=140) received 0.5 mg of cloprostenol (i.m.) at the day of enrolment and 14d later. All cows were re-examined by vaginoscopy 42-48 DIM. Proportion of cows cured, i.e. cows with clear, translucent or no mucus, 42-48 DIM (74.2 and 80.2% in groups CEF and CLP, respectively) was not affected by treatment group (P=0.09). The voluntary waiting period was set at 40 DIM. Artificial insemination (AI) submission rate, days to first service, first service conception rate, days open and proportion of cows pregnant did not differ between the groups. In conclusion, the systemic treatment with 1.0 mg/kg BW of ceftiofur on 3 consecutive days in cows with signs of clinical endometritis 21-27 DIM was equivalent to an intervention protocol consisting of two doses of cloprostenol in a 14-d interval.

Topics: Animals; Anti-Bacterial Agents; Cattle; Cattle Diseases; Cephalosporins; Cloprostenol; Dairying; Drug Administration Schedule; Endometritis; Female; Injections, Intramuscular; Insemination, Artificial; Luteolytic Agents; Pregnancy; Pregnancy Rate; Reproduction